<DOC>
	<DOCNO>NCT01961544</DOCNO>
	<brief_summary>This clinical study design open , single group , multi-center , phase 4 clinical study ass safety eribulin approve treatment patient Korea locally advance metastatic breast cancer receive two five prior chemotherapy regimen include anthracyclines taxanes advance disease . Subjects meet inclusion/exclusion criterion administer 1.4 mg/m2 investigational product intravenously 2-5 min day 1 day 8 every 21-day cycle . In case progression disease , unacceptable toxicity , withdrawal consent , judgment investigator treatment need stop , treatment investigational product stop , treatment termination assessment perform within 30 day last treatment .</brief_summary>
	<brief_title>Eribulin Mesylate Phase IV Clinical Trial Korean Patients With Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Female , Age great equal 20 year 2 . Patients histologically cytologically confirm carcinoma breast 3 . Patients locally advance metastatic carcinoma breast 4 . Patients receive two five prior chemotherapeutic regimen include antracycline taxane 2 regimen locally recurrent and/or metastatic disease 5 . Patients must prove refractory recent chemotherapy within six ( 6 ) month therapy 6 . Patients assessable lesion accord RECIST v 1.1 7 . Adequately maintain bone marrow function absolute neutrophil count ( ANC ) great equal 1.5 x 10^9 /L hemoglobin great equal 10.0 g/dl ( hemoglobin le 10.0 g/dL acceptable correct erythropoietin transfusion ) Platelet count great equal 100 x 10^9 /L 8 . Adequately maintain liver function Total bilirubin : le equal 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( case liver metastases less equal 5 x ULN ) 9 . Adequately maintain renal function Serum creatinine less equal 2.0 mg/dl Calculated creatinine clearance great equal 40 ml/min ( Cockcroft Gault formula ) 10 . Resolution chemotherapy radiationrelated toxicity Grade 1 severity low , except alopecia stable sensory neuropathy less equal Grade 2 11 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 12 . Life expectancy great equal 3 month 13 . Patients willing able comply study protocol duration study 14 . Patients provide write consent participate study Exclusion Criteria 1 . Patients receive chemotherapy , radiation , biologics , immunotherapy hormonal therapy within three week treatment start ( , palliative radiation enrol ) 2 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen 3 . Patients brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least four week start treatment study . Any sign and/or symptom brain metastasis must stable least four week start study treatment 4 . Patients meningeal carcinomatosis 5 . Significant cardiovascular impairment Myocardial infarction within past six month , unstable angina , history congestive heart failure NYHA class III IV , serious cardiac arrhythmia QTc prolongation ( Bazett 's Formula great 480 msec ) congenital long QT syndrome 6 . Severe/uncontrolled intercurrent illness/infection require administration antibiotic injection 7 . Patients process major surgery within four week participation clinical trial 8 . Patients prior malignancy within past five year breast cancer ( , treat nonmelanoma skin cancer carcinoma situ cervix exclude ) 9 . Patients know positive HIV status 10 . Patients receive genetic therapy investigational drug within 4 week treatment start expect receive prohibit medication 11 . Patients prior allergy Halichondrin B , derivative , active ingredient , dilute agent 12 . Patients receive investigational product registration study 13 . Patients pregnant , may possibly pregnant , lactate 14 . Patients agree practice contraception study period 15 . Patients participate clinical trial within 4 week screen 16 . Patients otherwise judge investigator sub investigator unsuitable inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
</DOC>